← Leaderboards
Jenica Upshaw
Tufts Medical Center
$1,703,494
Attributed
$1,703,494
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $818.6K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,703,494 · 2
By mechanism
K08$884,869 · 1
R37$818,625 · 1
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Iris Z Jaffe$20,757,672
- Michael E Mendelsohn$8,988,947
- Jennifer K. Chow$875,954
- Richard D Patten$1,288,412
- Francine M Foss$122,062
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsPreventDiagnosisLymphomaNewly DiagnosedPharmaceutical PreparationsClinical TrialsDexrazoxaneHeart FailureInfusion ProceduresCardiacNational Heart, Lung, And Blood InstituteOlder PatientCardiomyopathiesCardioprotectionCardiotoxicityComorbidityCardiovascular SystemAnthracyclineHeart DiseasesCancer TherapyHigh RiskChemotherapyProvider
Grant awards (8)
A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure$818,625
R37 · FY2025 · CA · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$128,976
K08 · FY2024 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$31,901
K08 · FY2024 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$162,497
K08 · FY2023 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$72,130
K08 · FY2023 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$162,997
K08 · FY2022 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$162,675
K08 · FY2021 · HL · contact PI
Prevention of Anthracycline Chemotherapy Cardiotoxicity$163,693
K08 · FY2020 · HL · contact PI